Camelot Portfolios LLC Purchases Shares of 3,510 IQVIA Holdings Inc. $IQV

Key Points

• Camelot Portfolios LLC acquired a new stake in IQVIA Holdings Inc., purchasing 3,510 shares valued at approximately $553,000 during the 2nd quarter.
• IQVIA reported $2.81 EPS for the last quarter, exceeding analyst estimates, and experienced a 5.3% revenue increase compared to the same quarter last year.
• Analysts have upgraded their price targets for IQVIA, with UBS Group setting a target of $225.00 and maintaining a "buy" rating.

Camelot Portfolios LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,510 shares of the medical research company's stock, valued at approximately $553,000.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. American National Bank & Trust purchased a new position in IQVIA during the 1st quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd grew its stake in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC grew its stake in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new position in IQVIA during the 1st quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. grew its stake in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Performance

NYSE IQV opened at $179.51 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.34. The stock has a market cap of $30.52 billion, a price-to-earnings ratio of 25.98, a price-to-earnings-growth ratio of 1.97 and a beta of 1.32. The business has a fifty day moving average of $187.01 and a 200-day moving average of $167.15. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the topic of several analyst reports. Robert W. Baird lifted their target price on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. UBS Group lifted their target price on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. William Blair reiterated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Evercore ISI lifted their target price on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Finally, Jefferies Financial Group upgraded IQVIA from a "hold" rating to a "buy" rating and lifted their target price for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus price target of $229.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.